TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be diagnosed with chronic PTSD, duration of 6 months or longer resulting from traumatic experience during military service;~* Have a CAPS score showing moderate to severe PTSD symptoms;~* Have had at least one unsuccessful attempt at treatment for PTSD either with talk therapy or with drugs, or discontinuing treatment because of inability to tolerate psychotherapy or drug therapy.~* Are at least 18 years old;~* Must be generally healthy;~* Must sign a medical release for the investigators to communicate directly with their therapist and doctors;~* Are willing to refrain from taking any psychiatric medications during the study period;~* Willing to follow restrictions and guidelines concerning consumption of food, beverages, and nicotine the night before and just prior to each experimental session;~* Willing to remain overnight at the study site;~* Agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session;~* Are willing to be contacted via telephone for all necessary telephone contacts;~* Must have a negative pregnancy test if able to bear children, and agree to use an effective form of birth control;~* Must provide a contact in the event of a participant becoming suicidal;~* Are proficient in speaking and reading English;~* Agree to have all clinic visit sessions recorded to audio and video~* Agree not to participate in any other interventional clinical trials during the duration of this study.~Exclusion Criteria:~5.3.2 Exclusion Criteria:~* Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control;~* Weigh less than 48 kg;~* Are abusing illegal drugs;~* Are unable to give adequate informed consent;~* Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary.~* Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the s

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose MDMA (Type: ACTIVE_COMPARATOR): Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
- Medium dose MDMA (Type: ACTIVE_COMPARATOR): Participants will receive 75 mg MDMA on each of two blinded experimental sessions
- Full dose MDMA (Type: EXPERIMENTAL): Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Protection Effect of Speeda® Rabies Vaccine for Human Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed~* Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months before injured~* The man-killer could found and detect whether it carries the virus~Exclusion Criteria:~* Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth~* Apply passive immunity preparation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- rabies vaccine (Type: EXPERIMENTAL): When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Heterozygous for F508del and an MF mutation (as defined in the protocol)~* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
- VX-659/TEZ/IVA TC (Type: EXPERIMENTAL): Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients with bipolar disorder (type I or type II) currently suffering from depression that is at least moderate in severity according to a psychiatrist.~* Currently using lithium.~* Female subjects can't be pregnant or become pregnant during the study.~Exclusion criteria:~* Actively suicidal.~* Rapid cyclers.~* Suffering from significant personality disorders.~* Alcohol or substance dependent or abusive.~* Suffering from significant physical conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Patients with rheumatoid arthritis (RA) who have not responded or have been intolerant to a single TNF-inhibitor therapy~* Initiated on treatment with MabThera/Rituxan or an alternative TNF-inhibitor therapy, in accordance with the relevant Summary of Product Characteristics~Exclusion Criteria:~* Patients whose second biologic therapy is given as part of a clinical trial studying RA treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
- Alternative TNFi (Type: None): Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent before starting the study-related procedures and examinations~* Patients who have the history of gastric and/or duodenal ulcer.~* A diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed LDA during the study treatment period.~Exclusion Criteria:~* Having gastric or duodenal ulcer (except for ulcer scar).~* History of esophageal, gastric or duodenal surgery, except for simple closure of perforation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole 20mg (Type: EXPERIMENTAL): Esomeprazole 20mg once daily oral
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients at least 20 years of age.~* Patients histologically diagnosed with peripheral T-cell lymphoma by pathological diagnosis of biopsied lesion.~* Relapsed or refractory patients with a treatment history of at least one regimen.~* Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm in maximum diameter on computed tomography performed.~* Patients expected to survive for at least 3 months.~* ECOG PS 0-2.~* Patients with adequate hemopoietic efficacy, liver and kidney function.~* Patients from whom written consent has been obtained prior to study initiation.~Exclusion Criteria:~* Patients who received a chemotherapy agent or a high dose of a systemic adrenocorticosteroid within 21 days prior to initial administration of the study drug.~* Patients who received radiation therapy, phototherapy, or electron beam therapy within 21 days prior to initial administration of the study drug.~* Patients who received another study drug within 28 days prior to initial administration of the study drug.~* Patients who received antibody therapy within 100 days prior to initial administration of the study drug.~* Patients with a history of allogeneic hematopoietic stem cell transplantation. Or patients with a history of autologous hematopoietic stem cell transplantation within 100 days prior to initial administration of the study drug.~* Patients with cerebral metastasis or central nervous system lesion or a past history.~* Patients with active multiple primary cancer. Or patients with a history of a malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years.~* Patients with severe cardiovascular disease.~* Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological investigation. Or patients positive for either HBc antibody or HBs antibody, and showing DNA more than sensitivity in HBV-DNA assay.~* Patients positive for CMV antigen on immunological investigation.~* Patients with infectious disease requiring treatment consisting of intravenous administration of antibacterial agent, fungicide, or antiviral drug.~* Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to have insufficient pulmonary function.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pralatrexate injection (Type: EXPERIMENTAL): Dietary Supplement: Vitamin B12, Folic Acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints.~* Active plaque psoriasis at screening and baseline.~Exclusion Criteria:~* Non-plaque forms of psoriasis (with exception of nail psoriasis).~* History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06700841 60 mg once daily (Type: EXPERIMENTAL): PF-06700841 60 mg once daily for 52 weeks
- PF-06700841 30 mg once daily (Type: EXPERIMENTAL): PF-06700841 30 mg once daily for 52 weeks
- PF-06700841 10 mg once daily followed by 60 mg once daily (Type: EXPERIMENTAL): PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
- PF-06700841 10 mg once daily followed by 30 mg once daily (Type: EXPERIMENTAL): PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
- Placebo once daily followed by 60 mg once daily (Type: PLACEBO_COMPARATOR): Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
- Placebo once daily followed by 30 mg once daily (Type: PLACEBO_COMPARATOR): Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer~  * Stage I-IIIA~ * Operable disease~* Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative~* Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1 of the following criteria:~  * 3-month/4-course anthracycline-based regimen~ * 6- to 8-month/course anthracycline-based regimen~ * 6- to 8-month/course non-anthracycline-based regimen~* Hormone receptor status:~  * Estrogen receptor negative~ * Progesterone receptor negative~PATIENT CHARACTERISTICS:~Age~* 18 to 49~Sex~* Female~Menopausal status~* Premenopausal~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception~* No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* No prior cytotoxic chemotherapy~Endocrine therapy~* No other concurrent hormonal therapy~Radiotherapy~* Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed~Surgery~* See Disease Characteristics~Other~* Concurrent participation in other therapeutic clinical trials, including SWOG-S0221, allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Standard Chemotherapy (Type: ACTIVE_COMPARATOR): Patients receive cyclophosphamide-containing chemotherapy alone.
- Chemotherapy Plus Goserelin (Type: EXPERIMENTAL): Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histological diagnosis of CD20+ B cell lymphoma subtypes: marginal zone lymphoma, grade 1-2 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma~* conjunctival localization alone (1EA stage; mono- or bilateral)~* at least one measurable lesion~* age \>/= 18 years~* ECOG-PS \</=3~* HIV 1-2 negativity~* at least one previous treatment (antibiotic or rituximab)~Exclusion Criteria:~* concomitant conventional (chemo-, radiation, immuno-), experimental (antibiotic) or corticosteroid anticancer therapy~* known allergy to rituximab~* systemic symptoms~* concurrent diagnosis of pemphigus~* postsurgical conjunctival scars

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intralesional rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study specific procedures~* Are willing and able to comply with procedures required in the protocol~* Adult male or female, at least 18 years old at the time of signing the informed consent~* Good health as determined by medical history, physical examination, vital signs, and investigator's judgment~Exclusion Criteria:~* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function~* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)~* Anticipated need for surgery or overnight hospitalization during the study~* Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study~* Known immunization or hypersensitivity to any botulinum toxin serotype~* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months~* Lower facial and neck hair, scarring (e.g., acne), or other abnormal variations that may interfere with photography (such that photograph is not acceptable)~* Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOTOX (Type: EXPERIMENTAL): BOTOX (OnabotulinumtoxinA) will be injected into the platysma muscle on Day 1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be injected into the platysma muscle on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete